Orgenesis Inc.
DelistedCIK 1460602fmd_0Y01YJZP30G47M90DQNVXXQRJWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Dec 01, 2009 to Dec 31, 2024, 59 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 6 | 10 | 19 | 4 | 8 | 36 | – | – | 1 |
| Cost of revenue | 4 | 8 | 7 | 11 | 18 | – | 37 | 5 | 6 | 2 |
| Gross profit | (1) | (1) | 3 | 8 | (14) | – | (1) | 31 | (6) | (1) |
| Realized investment gains (losses) | 0 | (0) | (1) | (1) | – | – | – | – | – | – |
| Research and development | 1 | 2 | 2 | 6 | 14 | 84 | 37 | 22 | 11 | 10 |
| Selling, general and administrative | – | – | – | – | 11 | 19 | 15 | 16 | 35 | 15 |
| Total operating expenses | – | – | – | – | – | – | – | – | – | – |
| Operating income | (7) | (11) | (11) | (15) | 22 | (96) | (17) | (10) | (54) | (40) |
| Other non-operating income (expense) | 2 | 1 | (2) | (3) | 1 | (1) | (1) | (2) | (2) | (5) |
| Income before taxes | (5) | (11) | (14) | (18) | 23 | (97) | (18) | (12) | (64) | (49) |
| Income tax expense | (1) | (2) | (1) | 1 | 0 | (2) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (4) | (9) | (12) | (19) | 23 | (95) | (18) | (12) | (65) | (49) |
| Net income | (4) | (9) | (12) | (18) | 24 | 1 | (18) | (15) | (55) | (48) |
| Net income to common shareholders | – | – | 12 | 19 | 6 | (101) | – | – | – | – |